A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

NCT07400744 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: QL2109
DRUG: Darzalex

Sponsor

Qilu Pharmaceutical Co., Ltd.